Sage Therapeutics (SAGE) Set to Announce Quarterly Earnings on Thursday

Sage Therapeutics (NASDAQ:SAGE) is scheduled to announce its earnings results before the market opens on Thursday, April 25th. Analysts expect the company to announce earnings of ($1.58) per share for the quarter. Parties interested in participating in the company’s conference call can do so using this link.

Sage Therapeutics (NASDAQ:SAGE) last announced its earnings results on Wednesday, February 14th. The biopharmaceutical company reported ($0.55) EPS for the quarter, topping the consensus estimate of ($1.28) by $0.73. The company had revenue of $77.97 million for the quarter, compared to analysts’ expectations of $60.15 million. Sage Therapeutics had a negative return on equity of 54.41% and a negative net margin of 626.32%. The business’s revenue for the quarter was up 2621.5% on a year-over-year basis. During the same quarter in the prior year, the business earned ($2.47) earnings per share. On average, analysts expect Sage Therapeutics to post $-6 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Sage Therapeutics Trading Down 3.3 %

Shares of SAGE opened at $12.89 on Tuesday. Sage Therapeutics has a 52 week low of $10.92 and a 52 week high of $59.99. The business’s fifty day moving average price is $19.42 and its two-hundred day moving average price is $20.82.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on SAGE shares. TD Cowen cut their target price on shares of Sage Therapeutics from $30.00 to $16.00 and set a “buy” rating on the stock in a report on Thursday, April 18th. Oppenheimer cut their price target on shares of Sage Therapeutics from $25.00 to $17.00 and set a “market perform” rating on the stock in a research report on Thursday, April 18th. Scotiabank dropped their target price on shares of Sage Therapeutics from $34.00 to $19.00 and set a “sector outperform” rating on the stock in a report on Thursday, April 18th. Needham & Company LLC restated a “hold” rating on shares of Sage Therapeutics in a research report on Thursday, April 18th. Finally, Morgan Stanley raised their price target on shares of Sage Therapeutics from $20.00 to $22.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 28th. Two investment analysts have rated the stock with a sell rating, thirteen have given a hold rating and three have assigned a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $39.28.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.